ZYMEWORKS INC. - COMMON STOCK

Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases

12 12 2024 08:30:00 提供 Nasdaq GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

21 11 2024 06:05:00 提供 Nasdaq GlobeNewswire

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

21 11 2024 06:00:00 提供 Nasdaq GlobeNewswire

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors

05 11 2024 06:00:00 提供 Nasdaq GlobeNewswire

Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results

31 10 2024 16:05:00 提供 Nasdaq GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

29 10 2024 06:00:00 提供 Nasdaq GlobeNewswire

Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

25 10 2024 06:00:00 提供 Nasdaq GlobeNewswire

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers

21 10 2024 06:00:00 提供 Nasdaq GlobeNewswire

Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024

10 10 2024 06:30:00 提供 Nasdaq GlobeNewswire

Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

18 9 2024 06:00:00 提供 Nasdaq GlobeNewswire

Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)

03 9 2024 16:30:00 提供 Nasdaq GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

22 8 2024 06:30:00 提供 Nasdaq GlobeNewswire

Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock

01 8 2024 16:10:51 提供 Nasdaq GlobeNewswire

Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results

01 8 2024 16:05:01 提供 Nasdaq GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

30 7 2024 06:30:00 提供 Nasdaq GlobeNewswire

Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer

25 7 2024 16:30:00 提供 Nasdaq GlobeNewswire

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate

22 7 2024 06:00:38 提供 Nasdaq GlobeNewswire

Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024

11 7 2024 06:30:00 提供 Nasdaq GlobeNewswire

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers

17 6 2024 06:00:00 提供 Nasdaq GlobeNewswire

Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer

10 6 2024 06:00:00 提供 Nasdaq GlobeNewswire